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Abstract 
 
Sunitinib and pazopanib are anti-angiogenic tyrosine kinase inhibitors (TKIs) 
used to treat metastatic renal cell carcinoma (RCC). However, the ability of these drugs 
to extend progression-free and overall survival in this patient population is limited by 
drug resistance. It is possible that treatment outcomes in RCC patients could be 
improved by rationally combining TKIs with other agents. Here, we address whether 
inhibition of the Ras-Raf-MEK-ERK1/2 pathway is a rational means to improve the 
response to TKIs in RCC. Using a xenograft model of RCC, we found that tumors 
which are resistant to sunitinib have a significantly increased angiogenic response 
compared to tumors which are sensitive to sunitinib in vivo. We also observed 
significantly increased levels of phosphorylated ERK1/2 in the vasculature of resistant 
tumors, when compared to sensitive tumors. These data suggested that the Ras-Raf-
MEK-ERK1/2 pathway, an important driver of angiogenesis in endothelial cells, 
remains active in the vasculature of TKI-resistant tumors. Using an in vitro 
angiogenesis assay, we identified that the MEK inhibitor (MEKI) trametinib has potent 
anti-angiogenic activity. We then show that, when trametinib is combined with a TKI in 
vivo, more effective suppresion of tumor growth and tumor angiogenesis is achieved 
than when either drug is utilized alone. In conclusion, we provide preclinical evidence 
that combining a TKI, such as sunitinib or pazopanib, with a MEKI, such as trametinib, 
is a rational and efficacious treatment regimen for RCC. 
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Introduction 
Kidney cancer is the 13th most common cancer worldwide with >300,000 new 
cases diagnosed each year. In the United States alone, there are ~60,000 new cases 
of kidney cancer diagnosed each year and ~14,000 deaths from kidney cancer each 
year (1). The majority of kidney cancers (90%) are renal cell carcinomas (RCC). 
Approximately 20% of patients presenting with a primary RCC have synchronous 
metastatic RCC (mRCC). A further 30% of patients will develop mRCC following 
surgery for the primary.  
Tumor angiogenesis stimulated by vascular endothelial growth factor (VEGF) 
is considered to be an essential driver in mRCC and angiogenesis inhibitors are 
efficacious in mRCC patients (2-4). Current standard of care in the first-line is treatment 
with one of two different anti-angiogenic tyrosine kinase inhibitors (TKIs): sunitinib or 
pazopanib. Both drugs inhibit receptors involved in angiogenesis, including VEGFR1-
3 and 3'*)5Įȕ (5-7), and have equal potency in their ability to extend progression 
free and overall survival in mRCC (8-11).  
However, approximately 20% of mRCC patients do not respond to these drugs 
(which is termed µintrinsic¶ or µearly¶ resistance to treatment). Moreover, most patients 
that respond initially will typically progress within 12 months of starting therapy 
(described as µacquired¶ or µlate¶ resistance to treatment). Median overall survival in 
mRCC patients treated with these agents remains in the region of 24 months (10). 
There is, therefore, a pressing need to find more effective treatment strategies for 
mRCC patients (2, 12). Importantly, functional imaging in mRCC patients showed that 
early resistance to TKIs can be correlated with incomplete suppression of 
angiogenesis, whilst acquired resistance is associated with tumor revascularisation 
after an initial period of response (7). These data suggest that a strong and sustained 
suppression of the tumor vascularisation process is key for ensuring the best response 
to TKIs in mRCC.  
Numerous mechanisms have been proposed to explain both early and late 
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resistance to anti-angiogenic therapy. One mechanism that has received considerable 
attention is redundancy in pro-angiogenic growth factor signalling (2, 12-14). Human 
cancers, including RCC, express numerous additional pro-angiogenic factors, 
including fibroblast growth factor 2 (FGF2), hepatocyte growth factor (HGF) and 
interleukin-8 (IL-8), which may stimulate the growth and survival of tumor blood vessels 
even when the VEGF-pathway is blocked (15-23). It may therefore be necessary to 
develop therapies that block the activity of multiple pro-angiogenic factors in these 
tumors.  
Most pro-angiogenic factors activate the Ras-Raf-MEK-ERK1/2 pathway in 
endothelial cells, a signalling pathway that promotes angiogenesis by triggering the 
proliferation, survival and migration of endothelial cells (24-27). In recent years there 
has been great interest in developing clinically effective small molecule inhibitors of 
MEK, the kinase which sits upstream of ERK1/2, as a means to inhibit the Ras-Raf-
MEK-ERK1/2 pathway in cancer (28). Moreover, impressive results have been 
obtained in metastatic melanoma when the MEK inhibitor trametinib is combined with 
the B-Raf inhibitor dabrafenib; with increased progression free and overall survival 
observed in the combination arm compared to B-Raf inhibition alone (29-31). These 
data provide compelling evidence that the MEK inhibitor trametinib can be safely and 
effectively combined with other kinase inhibitors in patients.  
However, the efficacy of MEK inhibition has yet to be tested in patients with 
mRCC. In the current manuscript, we present preclinical evidence that trametinib 
enhances the response to anti-angiogenic TKIs in renal cell carcinoma. 
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Materials and Methods 
 
Reagents 
Cell culture reagents: RPMI-1640, DMEM and M199 medium, fetal calf serum, 
collagenase-1 (Invitrogen), EBM-2 media, EGM-2 Bulletkit (Lonza Biologics), bovine 
brain endothelial mitogen (Serotech). Primary antibodies for western blotting: 
phospho-Thr-202/Tyr-204-ERK1/2 (M8159, Sigma-Aldrich, St Louis, MO, USA), total 
ERK1/2 (#9102, Cell Signalling Technology), HSC-70 (sc-7298, Santa Cruz 
Biotechnology). Primary antibodies for immunohistochemistry: endomucin (sc-65495, 
Santa Cruz Biotechnology), CD31 (550274, BD Biosciences), Ki67 (Ab15580, Abcam), 
phospho-Thr-202/Tyr-204-ERK1/2 (20G11, Cell Signaling Technology). Secondary 
antibodies: HRP- and biotin-conjugated (DAKO), fluorescently-conjugated (Life 
Technologies). Growth factors and inhibitors: VEGF-A (R&D Systems), FGF2 
(Peprotech), sunitinib, sorafenib, pazopanib (LC Laboratories), trametinib, selumetinib 
(Selleck Chemicals), PD184352 (Sigma-Aldrich). Unless otherwise stated, all other 
reagents were obtained from Sigma-Aldrich.  
 
Cell culture  
The 786-0 cell line was obtained from the American Type Culture Collection. 
Parental 786-0 cells, and the sub-lines 786-0-R and 786-0-S, were all cultured in 
RPMI-1640 plus 10% fetal calf serum (FCS). All three cell lines were confirmed as 
being 786-0 in origin by short tandem repeat (STR) typing, whilst Sanger sequencing 
confirmed that they all carried the VHL mutation reported for this cell line, 310delG 
(see Supplementary Methods). Human umbilical vein endothelial cells (HUVECs; TCS 
Cell Works) were cultured on gelatin-coated flasks in M199 supplemented with 20% 
FCS endothelial mitogen and 1 ng/ml heparin. Human 
angiogenic fibroblasts (HAFs; TCS Cell Works) were cultured in DMEM plus 10% FCS. 
Cells were regularly tested for mycoplasma and shown to be contamination free.  
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Xenograft models and treatment 
Female CB17 SCID mice (CB17/lcr-Prkdcscid/lcrlcoCrl) were obtained from 
Charles River UK. For 786-0 xenografts, mice were shaved on the flank and then 
injected subcutaneously with 3x106 786-0 cells. Once tumors reached 100 ± 200 mm3 
in size, the mice were randomized to receive treatment with sunitinib or vehicle. 
Tumors were measured using calipers and tumor volumes were calculated using the 
formula: (length x width2) x 0.5.  
In order to generate the 786-0-R and 786-0-S sub-lines, cells were isolated 
from sunitinib-treated 786-0 xenografts as follows: the relevant tumor was harvested, 
minced and digested in collagenase (1 mg/ml collagenase-1 in PBS supplemented 
with 1 mM MgCl2 and 1 mM CaCl2) at 37°C for 90 mins. Digested tissue was filtered 
and the cells collected by centrifugation. Cells were plated onto tissue culture flasks in 
RPMI-1640 plus 10% FCS and expanded in culture. To establish 786-0-R or 786-0-S 
xenografts, CB17 SCID mice were shaved on the flank and then injected 
subcutaneously with 3x106 cells. Once tumors reached 100 ± 200 mm3 in size, the 
mice were randomized to the treatment groups.  
The patient-derived xenograft (PDX) model was established from the tumour 
of a 71 year old male who underwent nephrectomy for clear cell RCC at the Royal 
Marsden hospital. Tumour fragments of ~2 mm3 in size were implanted 
subcutaneously into CB17 SCID mice through a small incision under anaesthesia. 
Mice were observed every week for the presence of palpable tumors. Subsequent 
passaging of tumors was achieved by harvesting the subcutaneous tumors and 
implanting tumor fragments subcutaneously into further recipient mice.  
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Sunitinib, trametinib and pazopanib were prepared in vehicle solutions suitable 
for oral dosing (sunitinib: 0.5% carboxymethyl cellulose, 300 mM NaCl, 0.4% Tween-
80, 0.9% benzyl alcohol adjusted to pH 6.0; trametinib: 0.5% hydroxypropylmethyl 
cellulose and 0.2% Tween-80; pazopanib: 0.5% hydroxypropylmethyl cellulose and 
0.1% Tween-80) as previously described (5, 32, 33). Mice were administered 0.2 ml 
of drug, or vehicle alone, by oral gavage at 40 mg/kg/day (sunitinib), 1 mg/kg/day 
(trametinib) or 30 mg/kg/day (pazopanib). In experiments where mice were dosed with 
sunitinib or vehicle only, mice received one dose by oral gavage each day. In 
experiments where mice received combination therapy, all mice in the experiment 
were dosed twice daily: vehicle, sunitinib or pazopanib was dosed first, followed by 
vehicle or trametinib 3 ± 4 hours later that same day. No overt signs of toxicity (such 
as weight loss) were observed in any treatment group, including mice treated with 
drugs in combination. 
 
Immunohistochemistry  
Immunohistochemistry was performed essentially as described (32). In brief, 
tumors were harvested from mice and bisected. Half the tumor was fixed in 4% w/v 
formalin, whilst the other half was embedded in OCT and frozen at -80°C. For 
endomucin staining, formalin fixed paraffin embedded sections were incubated with 
anti-endomucin antibody, followed by detection with a biotinylated secondary antibody 
and a DAB substrate kit (Vector). Slides were counterstained with heamatoxylin prior 
to mounting in DEPEX. Slides were scanned using a Hamamatsu Nanozoomer and 
viewed using NDPI software (Hamamatsu Photonics). The number of endomucin-
positive vessels in each section was counted manually. To calculate vessel density, 
the number of vessels present in the section was divided by the area of the section. 
Areas of necrosis were excluded from the quantification.  
Co-staining for CD31 and Ki67 or CD31 and pERK1/2 was performed on frozen 
sections that were fixed in formalin and incubated at 4°C overnight with primary 
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antibodies, followed by detection with appropriate fluorescently-conjugated secondary 
antibodies and counterstaining with DAPI. Immunofluorescence images were captured 
using an SP2 confocal laser-scanning microscope (Leica). The proportion of cells 
(endothelial or cancer cells) positive for Ki67 or pERK was calculated by manually 
counting the number of cell nuclei which stained positive per field and then dividing 
this by the total number of cells per field (5 fields per tumor sample were used).  
 
Western blotting 
Western blotting was performed essentially as described (27), see 
Supplementary Methods. 
 
In vitro angiogenesis assays 
Endothelial tubule formation assays were performed essentially as described 
(16), see Supplementary Methods. 
 
Ethical approval  
Ethical approval for animal experimentation was granted by the Institute of 
Cancer Research Animal Ethics Committee. All procedures were performed in 
accordance with UK Home Office regulations. Ethical approval for the use of human 
tissue collected from consented patients was obtained from the Royal Marsden 
Research Ethics Committee.  
 
Statistical Analysis  
Analysis of statistical significance was SHUIRUPHGXVLQJWKH6WXGHQW¶Vt test (P values 
of less than 0.05 were considered to be statistically significant). 
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Results 
 
Heterogeneous response to sunitinib in a preclinical model of renal cell 
carcinoma 
We established subcutaneous 786-0 xenografts in mice and once tumors 
reached 100-200 mm3 in volume, mice were randomized to treatment with either 40 
mg/kg sunitinib or vehicle. Tumors in the vehicle group (control) progressed rapidly, 
XQGHUJRLQJ 5-fold increase in tumor volume by 42 days compared to the start of 
treatment (Figure 1A). In contrast, the progression of tumors in the sunitinib-treated 
group was heterogeneous. This was not unexpected, since a heterogenous response 
to sunitinib in 786-0 xenografts has been decribed before (18). We took advantage of 
this heterogeneity and allocated tumors into three categories based on their response 
to treament: µsensitive¶ µearly resistance¶ or µlate resistance¶ (Figure 1B). Individual 
tumors were allocated to these categories based on the following criteria. Tumors 
undergoing 2.5-fold increase in tumor volume after 42 days (compared to the start of 
treatment) were allocated to the sensitive category (Figure 1B, left). Tumors that 
XQGHUZHQW 5-fold increase in volume after 42 days (compared to the start of 
treatment) were allocated to the early resistance category (Figure 1B, middle). Finally, 
tumorVWKDWXQGHUZHQW2.5-fold increase in volume by 50 days (compared to the start 
of treatment) wiWKSURJUHVVLRQWR5-fold increase in volume during the following 50-
100 days (compared to the start of treatment) were allocated to the late resistance 
category (Figure 1B, right). However, it should also be stated that  tumors in the 
sensitive category most likely represent the µsensitive¶ phase of tumor growth seen in 
the late resistance category.  
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Characterisation of the tumor vasculature in control, sensitive and resistant 
tumors 
Since sunitinib inhibits tumor growth in RCC principally by blocking tumor 
angiogenesis (34), we examined the vasculature in control, sensitive and early 
resistance tumors (all harvested after 42 days of treatment) and late resistance tumors 
(harvested after 99 - 101 days of treatment). Consistent with the potent anti-angiogenic 
activity of sunitinib, tumor vessel density was significantly decreased in all sunitinib-
treated categories compared to vehicle-treated tumors (Figure 1C). However, vessel 
density was significantly increased in both the early resistance category and late 
resistance category compared to the sensitive category (Figure 1C).  
Proliferation of tumor endothelial cells can also be used as a marker of tumor 
angiogenesis. Therefore, we quantified the proportion of Ki67-positive endothelial cells 
present in tumor vessels. No significant difference in the proportion of Ki67-positive 
endothelial cells was observed between the vehicle group and the sensitive category 
(Figure 1D). However, the proportion of Ki67-positive endothelial cells was significantly 
increased in both the early resistance category and late resistance category when 
compared to the sensitive category (Figure 1D).  
Finally, we quantified the presence of phosphorylated ERK1/2 (pERK1/2) in 
tumor endothelial cells. The proportion of endothelial cells positive for pERK1/2 was 
significantly increased in both the early resistance category and late resistance 
category compared to the sensitive category (Figure 1E).  
 
The MEK inhibitor trametinib has potent anti-angiogenic activity in vitro 
We next examined the ability of small molecule MEK inhibitors (MEKIs) to 
inhibit ERK1/2 activation in endothelial cells. Three MEKIs were tested: trametinib (33), 
selumetinib (35) and PD184352 (36). Human umbilical vein endothelial cells 
(HUVECs) were stimulated with a combination of VEGF and FGF2 in the presence of 
MEKI or vehicle alone, followed by blotting for pERK1/2 (Figure 2A-F). Blots were 
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performed in triplicate and densitometry measurements used to determine IC50s for 
the inhibition of ERK1/2 activation (Table 1). All three MEKIs suppressed ERK1/2 
activation in stimulated endothelial cells, with IC50s in the nanomolar range (Figure 2 
and Table 1). In parallel, we tested three anti-angiogenic TKIs: sunitinib, pazopanib 
and sorafenib. The MEKIs were more effective at inhibiting ERK1/2 activation than the 
TKIs (Figure 2 and Table 1). Moreover, the most effective inhibitor of ERK1/2 activation 
in endothelial cells was trametinib (IC50 = 1.3 nM).  
We then examined the anti-angiogenic activity of all six drugs (three MEKIs and 
three TKIs) using a previously described in vitro angiogenesis assay (16, 37). In brief, 
latex beads coated with HUVECs were embedded in a fibrinogen gel and incubated in 
the presence of VEGF and FGF2 in order to induce the formation of endothelial tubules 
(Supplementary Figure 2A). To measure inhibition of new tubule formation, assays 
were performed in the presence of drug from the first day of the assay onwards 
(Supplementary Figure 2B). Within the range of concentrations tested (10 pM to 10 
PM), all drugs exhibited anti-angiogenic activity, as measured by inhibition of tubule 
formation (Figure 3A and Table 1). The MEKI trametinib showed the most potent anti-
angiogenic activity (Figure 3A and Table 1).   
These results measure the ability of the tested drugs to block the formation of 
new tubules. We next tested their ability to regress pre-formed tubules. To do this, 
drugs were added to the assay at a time point after tubules were formed (7 days) and 
the extent of tubule regression was measured 48 hours later (Supplementary Figure 
2C). Only trametinib induced tubule regression at all concentrations tested (1, 10 and 
100 nM) (Figure 3B). For all other drugs, a dose of at least 100 nM was required to 
induce tubule regression (Figure 3B). 
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Combination of sunitinib with trametinib is an effective treatment regimen in 
vivo 
We then examined the ability of trametinib, sunitinib, or a combination of both 
drugs, to inhibit tumor growth in vivo. We used a sunitinib-refractory sub-line (786-0-
R) that we isolated from the parental 786-0 cell line (Supplementary Figure 2). Once 
786-0-R tumors reached 100-200 mm3 in volume, mice were randomized to receive 
vehicle alone, trametinib alone, sunitinib alone or a combination of sunitinib and 
trametinib. No overt signs of toxicity were observed in any treatment group, including 
mice treated with the drug combination. Treatment with single agent trametinib was no 
more effective than single agent sunitinib in suppressing tumor growth in this model 
(Figure 4A). However, the combination of sunitinib and trametinib was more effective 
than administering either drug alone (Figure 4A).  
To evaluate effects on tumor angiogenesis, vessel density was quantified in 
treated tumors (Figure 4B,C). Trametinib alone did not induce a significant reduction 
in tumor vessel density compared to vehicle. However, both single agent sunitinib and 
the sunitinib plus trametinib combination led to a significant reduction in vessel density 
compared to vehicle (Figure 4B).  Importantly, the strongest reduction in vessel density 
was observed with the combination therapy (Figure 4B).  
To address why these regimens differ in their potential to suppress tumor 
angiogenesis in vivo, we evaluated ERK1/2 phosphorylation in 786-0-R tumors that 
were harvested after 2 weeks of treatment. Phosphorylated ERK1/2 was quantified in 
tumor blood vessels and cancer cells separately. A modest, yet significant reduction 
in ERK1/2 phosphorylation was observed in blood vessels from tumors treated with 
either trametinib alone or sunitinib alone (Fig 4D), but the strongest inhibition of 
ERK1/2 phosphorylation in tumor blood vessels was observed in tumors treated with 
the sunitinib plus trametinib combination (Fig 4D). In contrast, no significant inhibition 
of ERK1/2 phosphorylation in cancer cells was observed in any treatment group (Fig 
4E).  
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To provide further evidence that the combination of sunitinib with trametinib 
can give rise to enhanced anti-angiogenic activity, we examined their activity again in 
the previously described in vitro angiogenesis assay. Importantly, we found that the 
combination of sunitinib with trametinib was more effective than either drug alone at 
inhibiting angiogenesis in vitro when the drugs were tested in this tubule formation 
assay at sub-threshold concentrations of drug (Supplementary Figure 4).  
 
Efficacy of trametinib in a discontinuous schedule or when added after 
progression or when combined with pazopanib 
Since the anti-tumor activity of single agent trametinib was no more effective 
than single agent sunitinib within our in vivo model, in our next experiments we focused 
on comparing the sunitinib-trametinib combination with sunitinib monotherapy. 
Sunitinib is typically administered in a discontinuous schedule in the clinic for 2 weeks 
on / 1 week off (2/1 schedule) or for 4 weeks on / 2 weeks off (4/2 schedule). Therefore, 
we examined discontinuous scheduling of treatment. Once 786-0-R tumors reached 
100 ± 200 mm3 in volume, mice were randomized to receive a 2/1 schedule of sunitinib 
or a 2/1 schedule of sunitinib plus trametinib. Again, we found that the combination 
was more effective than sunitinib alone in suppressing tumor growth (Figure 5A) and 
in suppressing tumor vessel density (Supplementary Figure 4A).   
We then tested the efficacy of switching to a combination of sunitinib plus 
trametinib in mice whose tumors had already progressed whilst on treatment with 
sunitinib. Mice bearing established 786-0-R tumors were treated with sunitinib alone 
for 28 days, during which time their tumors increased in volume approximately 2-fold 
compared to the start of treatment (Figure 5B). The same mice were then randomized 
to either continue on sunitinib alone for 14 days or switch to treatment with sunitinib 
plus trametinib for 14 days. Importantly, whilst tumors in the group that continued on 
sunitinib progressed, tumors that switched to the combination regressed (Figure 5B) 
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and had a significantly lower vessel density than tumors that remained on sunitinib 
(Supplementary Figure 4B).   
We also tested whether trametinib would be effective when combined with 
pazopanib. Mice bearing established 786-0-R tumors were randomized to receive 
trametinib alone, pazopanib alone or a combination of pazopanib and trametinib. The 
combination of pazopanib and trametinib was more effective than administering either 
agent alone (Figure 5C and Supplementary Figure 4C).  
 
Efficacy of trametinib combined with sunitinib in a PDX model of RCC 
We established a PDX model of RCC from the primary renal cancer of a 71 
year old male. Samples from four different viable tumor regions (regions 1-4) were 
grafted subcutaneously into mice (Figure 6A). In this first generation of the PDX, the 
only graft which took was from region 4 (Figure 6A). This tumor was passaged into 5 
further mice to establish the second generation of the PDX (Figure 6A). Established 
tumors from these 5 mice were then grafted into a further 20 mice to establish the third 
generation of the PDX (Figure 6A). The clear cell histology of the primary cancer was 
retained at each generation of the PDX (Figure 6B-E) and STR typing confirmed good 
concordance between the genotype of the original patient tumour and the genotype of 
the PDX (Supplementary Table 1). Sequencing of the PDX model confirmed the 
presence of a mutation in exon 3 of the VHL gene (464delT). This mutation has been 
previously reported in RCC and is predicted to generate a truncated version of VHL 
(38). We called this model ICR-RCC-01. 
Mice bearing third generation ICR-RCC-01 tumors were randomized to 
treatment. Trametinib alone was not effective at suppressing tumor growth compared 
to vehicle (Figure 6F). However, treatment with sunitinib alone suppressed tumor 
growth compared to vehicle (Figure 6F) and the combination of sunitinib with trametinib 
was more effective at suppressing tumor growth than administering sunitinib alone 
(Figure 6F). 
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Discussion 
Treatment outcomes in mRCC patients might be improved by rationally 
combining TKIs with other agents (2, 12, 39). In the current preclinical study, we 
addressed whether inhibition of the Ras-Raf-MEK-ERK1/2 pathway is a rational means 
to improve the response to anti-angiogenic TKIs in RCC. We found that 786-0 
xenografts responded heterogeneously to treatment with sunitinib, allowing us to 
define tumors as being µsensitive¶ µearly resistanW¶ or µlate UHVLVWDQW¶WRVXQLWLQLEBoth 
early and late resistant tumors showed significantly increased vessel density and 
significantly increased endothelial cell proliferation compared to sensitive tumors. This 
may mirror the clinical scenario in RCC, where early resistance to TKIs can be 
correlated with incomplete suppression of angiogenesis and where late resistance can 
be correlated with tumor re-vascularization after an initial period of response (7). 
Importantly, we also found elevated levels of phosphorylated ERK1/2 in the vessels of 
these early and late resistant tumors compared to sensitive tumors, showing that the 
Ras-Raf-MEK-ERK1/2 pathway remains active in the vascular endothelium of tumors 
that are resistant to TKI treatment. We then showed that combination treatment with 
sunitinib and the MEK inhibitor trametinib is significantly more effective at inhibiting 
tumor growth and tumour angiogenesis than utilizing either drug as a single agent.  
 In order to address why the MEKI plus TKI combination was more effective at 
limiting tumor growth and tumor angiogenesis in vivo, we quantified phosphorylated 
ERK1/2 in both tumor blood vessels and cancer cells in tumors harvested from treated 
mice. We found that the combination resulted in more effective inhibition of ERK1/2 
phosphorylation in tumor endothelial cells than either drug alone. However, ERK1/2 
phosphorylation in cancer cells was not significantly affected by the drug treatments. 
From these data we conclude that the superior anti-angiogenic activity of the 
combination in vivo is most likely due to the greater inhibition of the Ras-Raf-MEK-
ERK1/2 pathway in tumor endothelial cells when the drugs are combined. This superior 
anti-angiogenic effect then translates into a superior inhibition of tumor growth.  
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 However, we also acknowledge that the superior anti-tumor effect of the 
combination could arise through other mechanisms. For example, MEK-dependent 
recruitment of pro-angiogenic neutrophils to tumours has been shown to mediate 
resistance to VEGF-inhibiton in preclinical models and can be overcome by inhibiting 
the MEK pathway in vivo (40). Moreover, RCC cell lines resistant to sorafenib or 
sunitinib in vitro have increased expression of pERK1/2, suggesting that an activated 
Ras-Raf-MEK-ERK1/2 pathway may directly promote cancer cell survival during 
resistance to TKI treatment (41, 42). Taken together, these data suggest that co-
targeting of the VEGF pathway and the Ras-Raf-MEK-ERK1/2 pathway in RCC could 
potentially lead to improved responses due to multiple mechanisms, including 
enhanced inhibition of angiogenesis in endothelial cells (current study), inhibition of 
pro-angiogenic neutrophil recruitment  (40) and suppression of pro-survival signalling 
in cancer cells (41, 42).  
Although our data provide preclinical evidence that trametinib enhances the 
response to TKIs in RCC, translating combination treatment strategies such as this to 
the clinic can be challenging (39) because combining a TKI with a MEKI in patients 
could lead to unacceptable levels of toxicity. One strategy utilized to minimize toxicity 
in the clinic is to include planned treatment breaks in the dosing schedule. Importantly, 
we showed that the combination of sunitinib and trametinib was still more effective 
than sunitinib monotherapy when administered in a schedule that incorporated a 
planned treatment break. We also examined the effficacy of combining pazopanib with 
trametinib. We found that the combination of pazopanib and trametinib was more 
effective than pazopanib alone. Moreover, a recent phase I trial showed that the 
pazopanib plus trametinib combination is tolerable in patients with solid tumors at full 
dose of both drug (43). Although no patients with mRCC were included in that study, 
the results indicate combining a TKI with a MEKI is feasible in cancer patients.  
Taken together, these data support the concept of testing MEK inhibition in 
combination with TKIs in patients with mRCC. A randomized phase II clinical trial of 
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TKI versus TKI plus MEKI in patients with mRCC can be envisaged. The question also 
arises as to whether adding a MEKI to TKI therapy could improve outcome in patients 
who have already progressed on prior TKI therapy. Importanly, here we also showed 
that adding trametinib to single agent TKI can suppress tumor growth even in tumors 
that already progressed on prior TKI therapy. Therefore, it may also be appropriate to 
test this combination in the second line. 
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Table 1 Activity of MEKIs and TKIs for inhibition of ERK1/2 activation in 
endothelial cells and inhibition of endothelial cell tubule formation  
 
Drug Inhibition of ERK activation 
determined from western 
blots (IC50 ± SEM) 
 
Inhibition of endothelial cell 
tubule formation (IC50 ± SEM) 
   
Trametinib 1.33 ± 0.05 nM 
 
0.09 ± 0.02 nM 
PD184352 20.35 ± 13.21 nM 6.34 ± 3.73 nM 
 
Selumetinib 
 
6.60 ± 2.88 nM 7.33 ± 0.76 nM 
Sunitinib 
 
3174.33 ± 1564.04 nM 39.60 ± 8.35 nM 
Pazopanib 
 
640.75 ± 329.27 nM 2.75 ± 0.25 nM 
Sorafenib 
 
not determined 199.80 ± 11.40 nM 
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Figure legends  
Figure 1 Heterogeneous response to sunitinib in a preclinical model of renal cell 
carcinoma 
A,B. Mice with established subcutaneous 786-0 tumors were treated with 40 
mg/kg/day sunitinib or vehicle alone. Growth kinetics are shown for three 
representative tumors belonging to each category: vehicle-treated control tumors (A) 
and sunitinib treated tumors from the ¶VHQVLWLYH¶¶HDUO\UHVLVWDQFH¶RU¶ODWHUHVLVWDQFH¶ 
categories (B). Graphs show the change in tumor volume over time relative to start of 
treatment. Growth kinetics for all tumours included in the study are shown in 
Supplementary Figure 1. 
C. Tumor vessel density in the control, sensitive, early resistance and late resistance 
categories. Graph shows the density of endomucin-positive tumor vessels per mm2 r 
SEM (n = 6 tumors from each category). Example staining of endomucin is shown. 
D. Tumor vessel proliferation in the control, sensitive, early resistant and late resistant 
categories. Graph shows the percentage of endothelial cells with Ki67-positive nuclei 
per field r SEM (15 high power fields were analyzed from across 3 tumors in each 
category). Example staining of a Ki67-positive endothelial cell is shown. 
E. Phosphorylated ERK1/2 (pERK1/2) in tumor vessels from the control, sensitive, 
early resistance and late resistance categories. Graph shows the percentage of 
endothelial cells with pERK1/2-positive nuclei per field r SEM (15 high power fields 
were analyzed from across 3 tumors in each category). Example staining of a 
pERK1/2-positive endothelial cell is shown. 
nsd = no significant difference. * P <0.05,   ** P <0.01,   *** P <0.0001. Scale bar, 50 
PM (C) or 5 PM (D,E). 
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Figure 2 Inhibition of ERK1/2 activation in endothelial cells by MEKIs and TKIs  
A-F. Endothelial cells were serum deprived and lysed without stimulation (no stim) in 
the presence of vehicle (veh) alone or stimulated with VEGF and FGF2 in the presence 
of vehicle alone or trametinib (A), selumetinib (B), PD184352 (C), sunitinib (D), 
pazopanib (E) or sorafenib (F) at the indicated concentration. Cell lysates were then 
probed for phosphorylated ERK1/2 or total ERK.  
  
Figure 3 Anti-angiogenic activity of MEKIs and TKIs within an in vitro 
angiogenesis assay 
A. Inhibition of new tubule formation by drugs. HUVEC-coated beads were embedded 
in a fibrinogen gel and stimulated with VEGF and FGF2 for 7 days to induce tubule 
formation. Assays were performed to assess the activity of six drugs  (trametinib, 
selumetinib, PD184352, sunitinib, pazopanib or sorafenib) or vehicle alone. Graph 
shows tubule formation at the indicated drug concentration relative to the vehicle 
control r SEM (n = 3 independent experiments). 
B. Retraction of pre-existing tubules induced by drugs. Tubules were allowed to form 
for 7 days in the absence of drug and were then treated with vehicle or drug for 48 
hours. Change in tubule length that occured during the drug incubation period was 
quantified. Graph shows the percentage change in tubule length at the indicated drug 
concentration r SEM (n = 3 independent experiments). 
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Figure 4 Combination of trametinib with sunitinib is more effective than either 
drug alone in vivo  
A-C. Mice with established subcutaneous 786-0-R tumors were treated with vehicle 
alone, trametinib, sunitinib or a combination of sunitinib and trametinib. Graph in A 
shows tumor volume measured at the indicated timepoints r SEM. Graph in B shows 
tumor vessel density at endpoint (number of endomucin-positive vessels per mm2 r 
SEM is shown). Representative fields of endomucin staining from the indicated 
experimental groups are shown in C. n = 7 mice per experimental group.  
D,E. Mice with established subcutaneous 786-0-R tumors were treated for 2 weeks 
with vehicle alone, trametinib, sunitinib or a combination of sunitinib and trametinib. 
Graph in D shows phosphorylated ERK1/2 (pERK1/2) quantified in tumor vessels r 
SEM. Graph in E shows phosphorylated pERK1/2 quantified in cancer cells r SEM (20 
high power fields were analyzed from across 4 tumors in each experimental group).  
nsd = no significant difference, * P <0.05, ** P <0.01,  *** P <0.0001. 
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Figure 5 Efficacy of trametinib in a discontinuous schedule or when added after 
progression or when combined with pazopanib 
A. Efficacy of trametinib in a discontinous schedule. Mice with established 
subcutaneous 786-0-R tumors were treated with sunitinib on a two week on / one week 
off schedule (n = 10 mice) or a combination of sunitinib plus trametinib  on a two week 
on / one week off schedule (n = 10 mice) or they were treated with vehicle alone (n = 
5 mice). Graph shows tumor volume measured at the indicated timepoints r SEM. 
Bars below the x-axis indicate periods when drugs were administered.  
B. Efficacy of trametinib when added after progression. Mice with established 
subcutaneous 786-0-R tumors were treated with sunitinib for 28 days (n = 10 mice). 
On day 29, mice were randomized to either continue on sunitinib for 14 days (n = 5 
mice) or switch to treatment with sunitinib plus trametinib for 14 days (n = 5 mice). For 
the purpose of controls, mice with established subcutaneous 786-0-R tumors were 
treated with vehicle alone (n = 5 mice) or sunitinib plus trametinib for the duration of 
the experiment (n = 10 mice). Note: the vehicle group for this experiment was shared 
with the experiment show in panel A. Main graph shows tumor volume measured at 
the indicated timepoints r SEM. The inset graph shows percentage change in tumor 
volume between day 28 and day 42 for the mice that remained on sunitinib versus the 
mice that switched to sunitinib plus trametinib.  
C. Efficacy of trametinib when combined with pazopanib. Mice with established 
subcutaneous 786-0-R tumors were treated with vehicle alone, trametinib, pazopanib 
or a combination of pazopanib plus trametinib. Graph shows tumor volume measured 
at the indicated timepoints r SEM. n = 10 mice per group. 
** P <0.01,   *** P <0.0001. 
 27 
Figure 6 Efficacy of the combination regimen in a PDX model of RCC 
A. Tissue from four different regions (R1 to R4) of the primary tumor were grafted 
subcutaneously into recipient mice (1st generation). A tumor formed in the mouse 
grafted with region 4 was then passaged into a further five recipient mice (2nd 
generation). Tumors formed in these mice were then passaged into a further twenty 
recipient mice (3rd generation). 
B-E. Histology of the SDWLHQW¶Vprimary renal cancer (B) and the 1st (C), 2nd (D) and 
3rd (E) generation of the PDX.  
F. Mice with established subcutaneous tumors from the 3rd generation of the PDX 
were treated with vehicle alone, trametinib, sunitinib or a combination of sunitinib  plus 
trametinib. Graph shows tumor volume measured at the indicated timepoints r SEM.  
Scale bar, 30 PM. * P <0.05. 
 
